The Science of the Tube: Biology, Pathology, and Subtypes
At a Glance
Fallopian tube cancer often begins as a precancerous STIC lesion, taking about 7 years to develop into high-grade serous carcinoma. Pathologists use the SEE-FIM protocol to detect these microscopic cells and guide treatment based on your tumor's stage and genetic mutations like BRCA or TP53.
Understanding the biology of fallopian tube cancer can be empowering. While it was once thought to be a rare bystander to ovarian cancer, scientists now know that the fallopian tube is the “launchpad” for the most common and aggressive form of pelvic cancer: High-Grade Serous Carcinoma (HGSC) [1][1].
The 7-Year Window: From STIC to HGSC
The development of fallopian tube cancer is usually a slow, multi-step process. It often begins with a p53 signature—a small group of cells in the tube’s lining that have developed a mutation in the TP53 gene, which normally helps prevent cancer [1].
These cells eventually grow into a Serous Tubal Intraepithelial Carcinoma (STIC) [1]. A STIC is a “pre-invasive” lesion, meaning the cancer cells are present but have not yet broken through the surface to spread [1]. Research has shown that there is typically an average window of 6.5 to 7 years between the appearance of a STIC and the cancer’s spread to other organs [1]. This long progression period is why doctors now emphasize the importance of examining the fallopian tubes closely in women at high risk [1].
The Genetic Drivers: TP53 and BRCA
Two main genetic “drivers” are often involved in this process:
- TP53: Mutations in this gene are found in almost 100% of high-grade serous cases [1]. It is considered the “initiating event” that starts the transformation of healthy cells into cancerous ones [1].
- BRCA1 and BRCA2: These are genes that help repair DNA. If you have a mutation in one of these genes (either inherited from a parent or occurring just in the tumor), your cells are less able to fix DNA damage, making it easier for a STIC lesion to form [2][2].
Your doctor will likely order two types of genetic testing to check for these mutations: germline testing (via blood or saliva to check for inherited mutations) and somatic testing (testing the tumor tissue itself for mutations that only exist in the cancer).
The “SEE-FIM” Protocol
Because STIC lesions are microscopic, they can easily be missed if a pathologist only looks at a few slices of tissue. The gold standard for examining these tubes is the SEE-FIM protocol (Sectioning and Extensively Examining the FIMbriated end) [1].
In this protocol, the pathologist cuts the “fimbria” (the finger-like ends of the tube) into very thin longitudinal slices [1]. This allows them to see the entire surface area where most cancers begin. If your pathology report mentions SEE-FIM, it means your team did a thorough search for these early markers [1].
Staging Your Disease
Because fallopian tube, ovarian, and primary peritoneal cancers behave so similarly, they use a unified FIGO staging system [3]:
| Stage | What it means |
|---|---|
| Stage I | The cancer is strictly limited to the fallopian tube(s) [3]. |
| Stage II | The cancer has spread to other pelvic organs, like the uterus or ovaries [3]. |
| Stage III | The cancer has spread to the lining of the abdomen (peritoneum) or the lymph nodes [3]. |
| Stage IV | The cancer has spread to distant organs, such as the liver or lungs [3]. |
Current guidelines require your pathology report to specify the “primary” site—in your case, FT for Fallopian Tube—to ensure your treatment plan is tailored correctly [3].
Common questions in this guide
What is a STIC lesion in the fallopian tube?
What does the SEE-FIM protocol mean on my pathology report?
Why is the TP53 gene important in fallopian tube cancer?
What is the difference between germline and somatic genetic testing?
How long does it take for fallopian tube cancer to spread?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Was my surgery an 'R0' resection, meaning no visible tumor was left?
- 2.Am I a candidate for bevacizumab (Avastin) based on my stage and surgical outcome?
- 3.What are the results of my BRCA and HRD (Homologous Recombination Deficiency) tests?
- 4.Based on my genetic markers, which maintenance therapy path is most effective for me?
- 5.If I am HRD-negative, what are my maintenance therapy options?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (3)
- 1
High grade serous ovarian carcinomas originate in the fallopian tube.
Labidi-Galy SI, Papp E, Hallberg D, et al.
Nature communications 2017; (8(1)):1093 doi:10.1038/s41467-017-00962-1.
PMID: 29061967 - 2
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS, Burger RA, Enserro D, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(26)):2317-2328 doi:10.1200/JCO.19.01009.
PMID: 31216226 - 3
The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer.
Zeppernick F, Meinhold-Heerlein I
Archives of gynecology and obstetrics 2014; (290(5)):839-42 doi:10.1007/s00404-014-3364-8.
PMID: 25082067
This page explains fallopian tube cancer biology and pathology terminology for educational purposes only. Always consult your oncologist to interpret your specific pathology report and genetic testing results.
Get notified when new evidence is published on Malignant tumor of fallopian tubes.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.